Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG401 in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT04892342 is registered in ClinicalTrials.gov with Shanghai Escugen Biotechnology Co., Ltd as lead sponsor.

NCT NCT04892342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG401 in Subjects With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Shanghai Escugen Biotechnology Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
September 14, 2021
Completion date
June 30, 2025
Enrollment
156 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm of stomach, neoplasms, bladder, neoplasms, breast, neoplasms, lung, neoplasms,colorectal, neoplasms,ovarian